title: Oral glucose tolerance test after high-dose i.v. biotin administration in normoglucemic hemodialysis patients.
abstract: Abnormal glucose metabolism in uremia may result from a complex interplay between decreased insulin secretion and insulin resistance. Recent studies report beneficial effect of biotin administration in glucose metabolism in diabetic animals and in a small number of patients with diabetes mellitus. The aim of the present study was to evaluate the response of oral glucose tolerance test (OGTT) to the i.v. administration of large doses of biotin in hemodialysis patients. Eleven hemodialysis patients aged 56.90 +/- 11.20 (32-76) years on regular hemodialysis thrice a week for 2.72 +/- 1.79 (1-7) years were studied. Fasting venous plasma glucose, glucosylated hemoglobin (%GH), and plasma glucose concentration 2 h after the administration of a 75-g glucose load were measured before, and 2 weeks and 2 months after administration of 50 mg of biotin i.v. postdialysis, and after a 2-month washout period. During the study, dialysis schedule and patients' medication, diet, and dry weight were kept unchanged. OGTT was abnormal in 4 patients before biotin administration and became normal in 3 patients (75%). Our results offer support to the findings of other studies about the beneficial effect of biotin in experimental or clinical diabetes mellitus, and argue for the involvement of biotin in glucose metabolism.
authors.affiliation: Department of Nephrology, Aretaieon University Hospital, Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Koutsikos
authors.forename: C
authors.initials: C
authors.lastname: Fourtounas
authors.forename: A
authors.initials: A
authors.lastname: Kapetanaki
authors.forename: B
authors.initials: B
authors.lastname: Agroyannis
authors.forename: H
authors.initials: H
authors.lastname: Tzanatos
authors.forename: G
authors.initials: G
authors.lastname: Rammos
authors.forename: I
authors.initials: I
authors.lastname: Kopelias
authors.forename: B
authors.initials: B
authors.lastname: Bosiolis
authors.forename: O
authors.initials: O
authors.lastname: Bovoleti
authors.forename: M
authors.initials: M
authors.lastname: Darema
authors.forename: G
authors.initials: G
authors.lastname: Sallum
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001710:Biotin / Q000008:administration & dosage*; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects*; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test / Q000379:methods*; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D001710:Biotin; D001786:Blood Glucose; D005947:Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents